LM

Lockheed Martin continues strong partnership with Women in CyberSecurity (WiCyS)

Retrieved on: 
Tuesday, August 15, 2023
Workforce, Woman, Martin, WICY, Environment, Lockheed Martin, Lockheed, LM, Culture, Tier 1, Medical device, Arms industry

COOKEVILLE, Tenn., Aug. 15, 2023 /PRNewswire-PRWeb/ -- Since 2018, Lockheed Martin has been a WiCyS Tier 1 strategic partner that focuses on year-round engagement, especially encouraging inclusion and diversity changes within the cybersecurity field.

Key Points: 
  • COOKEVILLE, Tenn., Aug. 15, 2023 /PRNewswire-PRWeb/ -- Since 2018, Lockheed Martin has been a WiCyS Tier 1 strategic partner that focuses on year-round engagement, especially encouraging inclusion and diversity changes within the cybersecurity field.
  • Lockheed Martin actively promotes diversity and inclusion through its Business Resource Groups, Employee Networks, and diversity and inclusion councils.
  • One of these communities is a platform for its women in cybersecurity.
  • Lockheed Martin and WiCyS have a shared commitment to support those who have served as they transition to the workforce outside the military.

Crafted Exclusively for the North American Market, Lexus Celebrates the World Premiere of the All-New TX

Retrieved on: 
Friday, June 9, 2023
NX, Travel, EV, LBX, GX, Gasoline, GA, Lexus, V6, RX, SUV, LX, LM, RZ, Rail transport

The TX was developed exclusively for the North American market and was introduced as part of Lexus' efforts to craft cars that meet the specific needs of diverse customers and regions around the world.

Key Points: 
  • The TX was developed exclusively for the North American market and was introduced as part of Lexus' efforts to craft cars that meet the specific needs of diverse customers and regions around the world.
  • With their meticulously honed fundamental characteristics, the NX and LX were introduced in 2021 representing the dawn of the next-generation Lexus.
  • In 2023, Lexus unveiled the new LM, setting a new standard of luxury for chauffeur-driven cars.
  • By utilizing the GA-K platform, the new TX incorporates the unique Lexus driving experience known as the "Lexus Driving Signature," shared with other next-generation Lexus models such as the NX, LX, and RX.

World Premiere of the All-New Lexus GX

Retrieved on: 
Friday, June 9, 2023
Acceleration, NX, Travel, Shimoyama, LBX, GX, Torque, GA, V6, RX, SUV, LX, Traction, Nature, LM, RZ, EPS, Relaxation, Environment, Intuition, Fatigue, Rail transport, Tourism, Paint, Road, Lexus

TOKYO, June 9, 2023 - (JCN Newswire) - On June 8 (local time), Lexus unveiled the all-new GX during its world premiere in Austin, Texas, USA.

Key Points: 
  • TOKYO, June 9, 2023 - (JCN Newswire) - On June 8 (local time), Lexus unveiled the all-new GX during its world premiere in Austin, Texas, USA.
  • Positioned between the LX and RX, the GX is an SUV launched in 2002 primarily targeting the North American market featuring a body-on-frame structure.
  • The key concept of the new GX is to create a Lexus off-roader that symbolizes the central core of authentic Lexus off-roading.
  • "We have worked on the on-road performance of the GX so that you can feel the Lexus character from the moment you get into the GX and start driving.

Lexus Celebrates the World Premiere of the All-New LBX

Retrieved on: 
Monday, June 5, 2023
Spindle, NX, LBX, Face, Acceleration, Attention, GA, Carbon, LCD, RX, LX, Engineering, LM, MPV, RZ, Relaxation, Bridge, Fashion design, Rail transport, Lexus

2021 saw the dawn of a new generation of meticulously refined Lexus vehicles, beginning with the new NX and LX.

Key Points: 
  • 2021 saw the dawn of a new generation of meticulously refined Lexus vehicles, beginning with the new NX and LX.
  • In 2023, the Lexus line-up embarked on further expansion with products inspired by the diverse needs and desires of customers around the world.
  • - The expansion of driving support features, including the introduction of a 12.3-inch full LCD display meter
    "The new LBX stands for 'Lexus Breakthrough X(cross)-over'.
  • We believe that the LBX will bring a smile to the driver's face as they are filled with the true joy of driving a Lexus."

Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference

Retrieved on: 
Friday, August 11, 2023
Steps, Society, Plus Therapeutics, University of Texas System, Plus, Survival, Food and Drug Administration, SNO, Toxicity, Cerebrospinal fluid, CNS, Glioblastoma, Central nervous system, ASCO, Cancer, Spleen, Patient, University, Pakistan Society of Neuro-Oncology, LM, PSTV, Neurology, Liver, CSF, Neurosurgery, Neuro, Health, FDA, Therapy, Conference, Food, Safety, Pharmaceutical industry, Radiation, Rhenium

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today reported positive data from the ReSPECT-LM clinical study evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases (LM) at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

Key Points: 
  • The ReSPECT-LM clinical trial is funded, in part, by a 3-year, $17.6 million grant by the Cancer Prevention & Research Institute of Texas .
  • ET to discuss the data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda presented at the SNO/ASCO CNS Cancer Conference.
  • The webinar will feature a comprehensive discussion about the ongoing ReSPECT-LM Phase 1/2a dose escalation clinical trial, including key safety, tolerability, dosing, feasibility, and efficacy data.
  • A webinar with accompanying slides will be available in the Events page of the Investor Relations section of the Plus Therapeutics website beginning Friday, August 11, 2023 at 8:00 a.m.

Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

Retrieved on: 
Thursday, July 27, 2023
Society, Safety, SNO, Plus Therapeutics, CNS, Central nervous system, ASCO, Convection, Pakistan Society of Neuro-Oncology, HGG, CED, LM, PSTV, Decompression (diving), Therapy, Conference, Pharmaceutical industry, Rhenium

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

Key Points: 
  • AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.
  • All presentations will be showcased during the Poster Reception on Thursday, August 10, 2023, beginning at 5:30 p.m. PT/8:30 p.m.
  • ET.
  • [TIPS-23] Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial
    [TIPS-22] A two-part, Phase 1 study of Rhenium (186Re) Obisbemeda (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)

Global Titanium Dioxide Nanoparticles Market Report 2023: Photocatalytic Coatings to Inhibit Microbial Contamination - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
Chemicals, Plastics, Manufacturing, Titanium dioxide, Nanoparticle, Paint, Zinc oxide, LM, Water quality, Titanium, Cosmetics, DSSC, Absorption, Carbon, Silicon dioxide, Sunlight, Tungsten, Market, UV, Diamond, Quality control, Oxide, Nano, Particle size, Pigment

The Global Market for Titanium Dioxide Nanoparticles 2023-2033 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Market for Titanium Dioxide Nanoparticles 2023-2033 report has been added to ResearchAndMarkets.com's offering.
  • Titanium dioxide (TiO2) possesses a higher refractive index than diamond, does not absorb visible rays, and is highly chemically stable.
  • Rutile is the most stable, and anatase converts to rutile at temperatures in excess of 700 C.
    Microparticle titanium dioxide (TiO2) and nanoparticle Titanium Dioxide (TiO2-NPs) are markedly different materials.
  • Photocatalytic coatings are largely composed of nanoparticles of ceramic oxides, with most based on titanium dioxide (TiO2).

Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting

Retrieved on: 
Thursday, June 29, 2023
Glioma, Society, SNMMI, Ayub Ommaya, Safety, Cohort, Cerebrospinal fluid, Plus Therapeutics, MCI, ML, Patient, Risk, LM, PSTV, Decompression (diving), CSF, Neoplasm, Toxic leukoencephalopathy, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Food, Pharmaceutical industry, Vaccine, Medical imaging, OS, Rhenium

AUSTIN, Texas, June 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today reported positive interim updates from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM) at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, which took place June 24-27, 2023 in Chicago, Illinois.

Key Points: 
  • A single dose of rhenium (186Re) obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure.
  • The data demonstrates efficacy signals in a prognostically unfavorable patient population.
  • For each 10% increase in the Ratio of Treated to Total Tumor Volume, the risk of death decreases by 66.9% (p=0.002).
  • “As Phase 1 trials are designed for safety, statistically significant correlations between dose and overall survival are unusual.

Callibra, Inc. Launches New iCompose™ Tool for Sophisticated Content Library Management and Document Generation for Partner EMRs, Telehealth, and Clinical Systems

Retrieved on: 
Tuesday, June 27, 2023
Maintenance, SCP, Education, EMR, API, Health, GA, Language, Document, MS, Hospital, Documentation, Patient, LM, Medical device, Nursing, MD

"The content included is always up to date for zero content maintenance by our staff, zero downtime for updates, and we can add an unlimited amount of custom content as well.

Key Points: 
  • "The content included is always up to date for zero content maintenance by our staff, zero downtime for updates, and we can add an unlimited amount of custom content as well.
  • Designed specifically for the healthcare industry, iCompose™ provides an incredibly easy way to add extensive robust features for library management and document generation to any application, without extensive coding.
  • The iCompose™ platform consists of two powerful non-visual API products licensed together or separately: Library Manager (LM) and Document Generator (DG).
  • A physician-led, clinical services provider, SCP partners with hospitals and health systems, empowering clinicians to deliver high-quality, cost-effective patient care throughout the entire patient journey.

Bastyr University Graduates Expand Health Care Workforce When America Needs it Most

Retrieved on: 
Monday, June 26, 2023
Bastyr University, WA, Curriculum, Abdirahman Farole, Ageing, CLC, Medicine, Research, Doctor of Philosophy, Student, Public health, Metabolism, Nature, LM, Benaroya Hall, CPM, Liberty Station, San Diego, Health, Nursing, Management, Acupuncture, Nutrition, Psychology, Midwifery

KENMORE, Wash., June 26, 2023 /PRNewswire-PRWeb/ -- Bastyr University, with campuses in Kenmore Washington and San Diego California, celebrates graduation for 218 mostly doctorate and master's degree students.

Key Points: 
  • Bastyr University issues 96 naturopathic doctorates for the June 2023 graduating class, and graduate degrees in Acupuncture, Midwifery, Nutrition, Psychology, and Public Health.
  • KENMORE, Wash., June 26, 2023 /PRNewswire-PRWeb/ -- Bastyr University, with campuses in Kenmore Washington and San Diego California, celebrates graduation for 218 mostly doctorate and master's degree students.
  • Bastyr University is a nonprofit, private university offering doctoral, graduate, and undergraduate degrees, with a multidisciplinary curriculum in science-based natural health and medicine.
  • Recognized globally for its rigorous curriculum and strong research, Bastyr University has campuses in Kenmore, Washington, and San Diego, California.